Citation Impact
Citing Papers
Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
2015
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2017 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
2013
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
A Comprehensive Review of Noninvasive Liver Fibrosis Tests in Pediatric Nonalcoholic Fatty Liver Disease
2015
Dose-Finding Study of Rivaroxaban in Hemodialysis Patients
2015
Xylosyltransferase II is the predominant isoenzyme which is responsible for the steady-state level of xylosyltransferase activity in human serum
2015 StandoutNobel
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
2006 Standout
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
The impact of data transformations on concentration–response modeling
2012
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Increased serum xylosyltransferase activity in patients with liver fibrosis
2009
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
2010
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network
2011
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
2016
Oral Anticoagulant Therapy
2012 Standout
New Antithrombotic Drugs
2012
Rivaroxaban
2011
Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease
2008
Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients
2004
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
2008
Psoriasis
2021 Standout
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
2008 Standout
Non-alcoholic fatty liver disease: The mist gradually clears
2008
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
2007
The NAFLD fibrosis score
2007 Standout
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
2005
Antithrombotic Therapy for VTE Disease
2012 Standout
Dose-Response Analysis Using R
2015 Standout
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
2010
Non-alcoholic fatty liver disease
2021 Standout
A comparison of fibrosis progression in chronic liver diseases
2003
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease
2019
Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome
2011
Transient Elastography for the Noninvasive Assessment of Liver Fibrosis: A Multicentre Canadian Study
2010
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
2007
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
2012 Standout
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
2010 Standout
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement
2005
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis
2007
Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification
2010
Advances in functional and molecular MRI technologies in chronic liver diseases
2020
New anticoagulants: how to deal with treatment failure and bleeding complications
2011
Mechanical Stretch Induces Epithelial-Mesenchymal Transition in Alveolar Epithelia via Hyaluronan Activation of Innate Immunity
2011
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Molecular MRI of collagen to diagnose and stage liver fibrosis
2013
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
2013
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2008
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis
2016
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
2006 Standout
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
2009
Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation
2012
Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C†
2005
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
2010 StandoutNobel
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2018
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement
2009 Standout
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index
2005
Noninvasive markers of hepatic fibrosis: Are they ready for prime time in the management of HIV/HCV co-infected patients?
2005
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
2013
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Reproductive Disorders in Pubertal and Adult Phase of the Male Rats Exposed to Vinclozolin during Puberty
2004
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study
2008
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
2006
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection
2005
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
2007 Standout
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2017 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers
2019
The Halogen Bond
2016 Standout
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)
2007
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
2017
Design, Structure−Activity Relationships, X-ray Crystal Structure, and Energetic Contributions of a Critical P1 Pharmacophore: 3-Chloroindole-7-yl-Based Factor Xa Inhibitors
2008
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Nonalcoholic Fatty Liver Disease
2015 Standout
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Works of Michael Becka being referenced
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
2010
Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects
2003
Serum markers predict liver fibrosis
2001
Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects
2006
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
2005
Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects
2007
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
2005
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
2013
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin
2006
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1
2007
Feasibility and potential gains of enhancing the subacute rat study protocol (OECD test guideline no. 407) by additional parameters selected to determine endocrine modulation. A pre-validation study to determine endocrine-mediated effects of the antiandrogenic drug flutamide
2001
Serum markers detect the presence of liver fibrosis: A cohort study
2004
Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects
2007
Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
2006
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
2008
Automated assays of serum markers of liver fibrosis predict histological hepatic fibrosis.
2000
Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
2013
Naproxen Has No Relevant Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.
2005
The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor.
2006
Effects of Single-Dose BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor - in Subjects with Extreme Body Weight.
2005
The effect of food on the absorption and pharmacokinetics of rivaroxaban
2013